Sonnet Biotherapeutics Number Of Shares Shorted vs. Price To Book
| SONN Stock | USD 1.56 0.03 1.89% |
For Sonnet Biotherapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sonnet Biotherapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sonnet Biotherapeutics Holdings utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sonnet Biotherapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sonnet Biotherapeutics Holdings over time as well as its relative position and ranking within its peers.
Sonnet |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.35) | Revenue Per Share 0.019 | Quarterly Revenue Growth (0.50) | Return On Assets (0.97) | Return On Equity (2.65) |
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Sonnet Biotherapeutics Price To Book vs. Number Of Shares Shorted Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Sonnet Biotherapeutics's current stock value. Our valuation model uses many indicators to compare Sonnet Biotherapeutics value to that of its competitors to determine the firm's financial worth. Sonnet Biotherapeutics Holdings is rated below average in number of shares shorted category among its peers. It is rated below average in price to book category among its peers . The ratio of Number Of Shares Shorted to Price To Book for Sonnet Biotherapeutics Holdings is about 19,411 . As of the 21st of December 2024, Price To Book Ratio is likely to grow to 4.88. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sonnet Biotherapeutics' earnings, one of the primary drivers of an investment's value.Sonnet Price To Book vs. Number Of Shares Shorted
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Sonnet Biotherapeutics |
| = | 40.12 K |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Sonnet Biotherapeutics |
| = | 2.07 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Sonnet Price To Book Comparison
Sonnet Biotherapeutics is currently under evaluation in price to book category among its peers.
Sonnet Biotherapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Sonnet Biotherapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sonnet Biotherapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Sonnet Biotherapeutics' change in net profit over the period of time. It can combine multiple indicators of Sonnet Biotherapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -202.1 K | -212.2 K | |
| Operating Income | -11.8 M | -4.7 M | |
| Income Before Tax | -7.4 M | -4.9 M | |
| Total Other Income Expense Net | 4.4 M | -162.9 K | |
| Net Loss | -7.4 M | -4.9 M | |
| Net Loss | -17.4 M | -18.3 M | |
| Non Operating Income Net Other | -556.1 K | -528.3 K | |
| Net Loss | -16.1 M | -16.9 M | |
| Income Tax Expense | 162.9 K | 154.7 K | |
| Interest Income | 606.2 K | 955 K | |
| Net Interest Income | -187.3 K | -177.9 K | |
| Change To Netincome | 9.9 M | 10.4 M | |
| Net Loss | (11.35) | (15,593) | |
| Income Quality | 1.16 | 0.16 | |
| Net Income Per E B T | 0.76 | 0.87 |
Sonnet Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Sonnet Biotherapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sonnet Biotherapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sonnet Biotherapeutics' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Sonnet Biotherapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Crypto Correlations Now
Crypto CorrelationsUse cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
| All Next | Launch Module |
Use Investing Themes to Complement your Sonnet Biotherapeutics position
In addition to having Sonnet Biotherapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Hotels Thematic Idea Now
Hotels
Hotels, inns, motels, and other companies providing lodging and hospitality services. The Hotels theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hotels Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
To fully project Sonnet Biotherapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Sonnet Biotherapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Sonnet Biotherapeutics' income statement, its balance sheet, and the statement of cash flows.